Correction to: Leukemia (2010) 25, 2100–2109; doi:10.1038/leu.2010.212
Owing to a typesetting error, the following sentence was incorrectly printed in the abstract section of the article:
‘The novel inhibitor of apoptosis (IAP), LCL161, was observed to potentiate the effects of tyrosine kinase inhibition against leukemic disease both in the absence and presence of a stromal protected environment. LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease in vitro and potentiated the activity of both kinase inhibitors against leukemic disease in vivo.’
The correct version is as follows:
‘The novel IAP inhibitor, LCL161, was observed to potentiate the effects of tyrosine kinase inhibition against leukemic disease both in the absence and presence of a stromal-protected environment. LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease in vitro and potentiated the activity of both kinase inhibitors against leukemic disease in vivo.’
The publishers would like to apologize for this error.
Additional information
The online version of the original article can be found at 10.1038/leu.2010.212
Rights and permissions
About this article
Cite this article
Weisberg, E., Ray, A., Barrett, R. et al. Erratum: Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 25, 1221 (2011). https://doi.org/10.1038/leu.2011.83
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.83
